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A Ab bs st tr ra ac ct t
When BRCA1/2 genetic susceptibility testing was introduced in the clinic in the mid-nineties, the “Huntington
protocol” was used in the counselling of individuals applying for genetic testing. This protocol includes at least
three sessions with a certain reflection period before blood sampling. Evidence on the psychological impact of
BRCA1/2 genetic susceptibility testing has been accumulating in the last years. We will give a short overview of
these psychological studies in order to reflect the need of using the extensive Huntington protocol in the counselling
of individuals applying for BRCA1/2 genetic susceptibility testing. A shortened and more flexible BRCA1/2
counselling protocol is delineated, in which the attention is focused on the needs and strengths of the individual. 
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I In nt tr ro od du uc ct ti io on n
When genetic susceptibility testing for hereditary
breast and/or ovarian cancer was introduced in the
nineties, professionals were concerned about the
psychological consequences of learning one’s genetic
status. Women carrying a BRCA1/2 mutation have to
deal with considerable health risks [1-3] and are
confronted with difficult choices concerning risk
management. Mutation carriers can opt for regular
surveillance, for prophylactic mastectomy and/or
prophylactic bilateral salpingo oophorectomy, and/or
for chemoprevention trials. Besides important health
risks and the far-reaching impact of risk management
options,  these  women  may  be  psychologically
vulnerable due to unresolved loss experiences [4, 5].
Many have witnessed the disease in relatives and have
lost a mother or sister, possibly leaving young children
behind. Furthermore mutation carriers risk to pass or
to have passed the mutation onto their children with
all the above-mentioned consequences for them. 
T Th he e   H Hu un nt ti in ng gt to on n   p pr ro ot to oc co ol l
Because of the potentially far-reaching implications
of  BRCA1/2 susceptibility  testing,  the  “Huntington
protocol” was adopted for the counselling of unaffected
individuals who wanted to know whether they had
inherited a familial BRCA1/2 mutation. This “Huntington
protocol” has a long history. As the availability of DNA
analysis for the HD gene was set to become a reality, the
Committee of International Huntington Association and
the Working Group on Huntington’s disease of the World
Federation of Neurology gave consideration to the
manner in which these tests should be carried out
(IHA/WFN 1994). In general, the guidelines recommend
that individuals at risk who participate in predictive testing
programmes  are  seen  for  two  to  four  counsellingH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 20
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sessions, spread over a 3-month period, before disclosure
of the test results. Predictive testing requires informed
consent by the individual at risk, and the provision of
psychological support. If the test is abnormal, counselling
must be available for the family and others involved. The
starting point is that predictive tests should be offered only
to individuals at risk who have had the appropriate
counselling, are fully informed, and wish to proceed.
Genetic centres providing the predictive test have been
committed to the use of the international guidelines.
Admittedly, after 15 years, testing centres have developed
their own local protocols and guidelines, based on
experience and local or national rules, but what they have
in common is the requirement for multiple interviews
before  a test  result  is  disclosed.  The  number  and
complexity varies, partly due to the number of associated
psychological and other evaluations, but the basic
structure involves at least the series shown in Table 1. 
The expectation of an increase of test requests for
a great variety of hereditary disorders in the near future
leads us to reconsider the need for such an extensive,
time-consuming  protocol  in  the  counselling  of
individuals at risk, including those who may carry
a familial BRCA1/2 mutation. What have the lessons
of clinical experience and research provided so far? 
T Th he e   p ps sy yc ch ho ol lo og gi ic ca al l   i im mp pa ac ct t   o of f   g ge en ne et ti ic c   t te es st ti in ng g
Several  psychological  studies  have  now  been
conducted to determine the psychological impact of
genetic susceptibility testing for BRCA1/2. In most studies
groups of tested individuals were followed prospectively.
Generally, the assessment took place before result
disclosure and several weeks or months after result
disclosure. Results from these studies suggest that
participants  generally  cope  well  with  genetic
susceptibility testing. Non-mutation carriers reported
a decline in psychological distress several weeks and
months after result disclosure. Mutation carriers showed
a stable or decreasing level of distress shortly after result
disclosure [6-8] and up to 12 months after result
disclosure [9-11]. Five years after result disclosure the
level of distress increased again in both mutation carriers
and non-mutation carriers [12]. On the whole the mean
level of psychological distress remained underneath the
clinical threshold, indicating little need for intervention
[6-12]. In women affected by cancer also no adverse
psychological reactions have been observed following
genetic testing. They reported a decrease in anxiety and
no change in depression rates one month after result
disclosure [13]. Remarkably, the prospect of undergoing
genetic testing was rated as less distressing than the
high risk status or the diagnosis of cancer by women at
risk and women with a personal and familial history of
breast and/or ovarian cancer [14]. 
The occurrence of mental health problems was low.
No unusually high levels of psychiatric disorder were
detected in a group of 315 unaffected individuals from
families with a known mutation of BRCA1/2 [15]. 
In another study [16] it was concluded that of 211
women with a previous history of breast and/or ovarian
cancer and 253 unaffected women at risk remarkably
few women reported psychological distress and met
criteria for psychiatric disorder like depression, anxiety
disorder, or alcohol abuse. Compared to women from
primary care and community settings, they had lower
rates of psychiatric disorder. 
In summary, no elevated distress levels and a low
prevalence  of  mental  health  problems  have  been
observed  both  before  and  after BRCA1/2 genetic
susceptibility testing. The participants of the studies
described here wanted to know their genetic risk status
and  may  therefore  consist  of  a self-selected  and
psychologically stable subgroup of at risk individuals.
Despite the psychological stability of the majority of the
group,  we  emphasise  that  a subset  of  women
undergoing genetic susceptibility testing for BRCA1/2
reports a level of distress that warrants clinical attention. 
N Ne ee ed d   f fo or r   h he el lp p? ?   
The request for psychological support proved to be
rare in the short term [8]. Counselees who were
T Ta ab bl le e   1 1. .   P Pr re ed di ic ct ti iv ve e   t te es st ti in ng g   f fo or r   H Hu un nt ti in ng gt to on n’ ’s s   d di is se ea as se e
Session one
– Sociodemographic details
– Confirmation of family and clinical data
– Assessment of impact of HD and test results
– Assessment of knowledge of HD and presymptomatic testing
– Reasons for requesting prediction
– Neurological examination*
Session two
– Assessment of psychological, personality and social 
resources (using standardized instruments*) 
– Further counselling and discussion on disclosure session
– Nomination of professional support
– Signing of consent form
– Final blood sample
Session three
– Disclosure of test results
Formal follow-up
– 2 days-1 week (telephone) 
– 3 months
– 12 months
* Genetic centres differ in the application of neurological examination 
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referred for psychosocial help generally had more
problems with issues like loss and family or partner
relationships than with the concern of developing breast
cancer [17]. In the five years following testing about
half  of  the  mutation  carriers  and  a third  of  the
non-carriers were found to have asked for professional
support for psychological problems [12]. 
Several efforts have been made to identify counselees
who risk suffering from psychological adverse reactions.
An important precursor is pre-test psychological distress.
Women reporting more psychological distress at the time
of blood sampling generally continue to report higher
distress levels after receiving the result [7, 8]. In the main
these women are younger [5, 15, 18] and interested in
prophylactic surgery [5]. 
Another factor was having an intimate relationship.
Unmarried women seeking genetic counselling for
a family history of breast/ovarian cancer reported more
distress than married women in one study [18]. However
another study [19] found equal levels of distress in
married and unmarried women, but more distress in
women with unhappy marriages. A study by Wylie et al
[20] evaluated the effects of the support and distress of
spouses on BRCA1/2 mutation carriers. Carriers who
perceived their spouse to be anxious and non-supportive
had higher distress levels one week after result disclosure
than carriers who perceived their spouse to be supportive
and anxious or low anxious and non-supportive. Carriers
who perceived their spouse to be both supportive and
low anxious had the lowest distress levels. In carriers with
a non-supportive, anxious spouse at the time of testing,
distress remained elevated up to two years after testing.
The  familial  context  may  also  be  of  importance.
BRCA1/2 mutation carriers who were the first to be tested
experienced  more  distress  [21].  Non-carrier  men
reported more distress when they had carrier siblings
and carrier women reported more distress when tested
siblings had mixed results. 
Several other studies have concentrated on coping,
like the anticipation of the feelings following a positive
result. Women who underestimated their feelings of
distress following a positive test result, reported more
psychological distress six months after having received
the result [22]. A monitoring coping style, i.e. being
very vigilant to threatening information, resulted in more
psychological distress while waiting for the genetic test
result [23], but not after receiving results [11, 23]. 
Decliners of genetic testing may also be more
vulnerable to psychological distress. Women with high
levels of baseline distress who declined genetic testing
reported an important increase in depression rates [24].
Another study however did not find any psychological
vulnerability in a (small) clinical sample of women at
risk who did not opt for genetic testing [25]. 
A A   B BR RC CA A1 1/ /2 2 c co ou un ns se el ll li in ng g   p pr ro ot to oc co ol l
Genetic counselling should be tailored to the needs
and capacities of its target group. If the target group
generally has enough psychological resources to cope
with genetic testing, our energy should be directed to
the individuals who risk being unable to cope with it.
Therefore we suggest adapting the Huntington protocol
to the needs and strengths of our BRCA1/2 counselees.
The  shortened  BRCA1/2 protocol  we  propose  is
depicted in Table 2. It comprises at least two sessions
with a genetic counsellor and additional counselling
suited to the needs of the counselee. This BRCA1/2
protocol could serve as a model for genetic susceptibility
testing of other hereditary cancers such as HNPCC. 
In the first session, careful exploration of the possible
impact of testing upon the individual at risk and others
involved enables the counselees and their partners to
recognise the potential risk factors for inadequate coping.
If there are any such factors, additional professional
attention from a psychologist or social worker may be of
help to anticipate untoward experiences after disclosure
of test results. A second session with the counsellor can
be offered when unanticipated information or facts
emerge in the first session. This enables the counselee to
reflect somewhat longer upon the possible consequences
T Ta ab bl le e   2 2. .   G Ge en ne et ti ic c   s su us sc ce ep pt ti ib bi il li it ty y   t te es st ti in ng g   f fo or r   B BR RC CA A1 1/ /2 2
First counselling session with a genetic counsellor
– Assessment of a priori knowledge concerning BRCA1/2
mutations and genetic testing and provision of risk 
information
– Assessment of impact of the test result
– Assessment of need to refer to a psychosocial worker
– Decision counselling
– Blood sampling
No blood sampling but a second counselling session with 
a genetic counsellor or psychosocial worker if: 
– counselee experiences provided information as very unfamiliar
or shocking or decision making was not thorough 
– other ‘unfinished business’ comes up such as relational 
conflicts, communication problems with relatives, worries 
about (future) children 
– anticipation of inadequate coping with the test result
– the counselee is younger than 25
Disclosure session 
– Disclosure of the test result by the genetic counsellor
– Assessment of need to refer to a psychosocial worker
– Referral to a specialist (for carriers) 
Formal follow-up for mutation carriers: 
– Follow-up interview by phone after 2-3 weeks 
– Optional information seminar with experts (geneticist, 
oncologist, surgeon, gynaecologist) once a year
– Optional mutation carrier support groupH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 22
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and to be more certain to make a thorough decision.
Also after the session in which the test result is disclosed,
follow-up support by a psychologist or social worker can
be offered if needed. Otherwise a follow-up interview by
phone and mentioning the possibilities of additional
counselling may be sufficient. It is mandatory for the
genetic counsellor to master specific communication skills
and knowledge about the psychological risk factors,
which enables him to identify those individuals who need
additional support. 
C Cu ur rr re en nt t   p pr ra ac ct ti ic ce e   a an nd d   f fu ut tu ur re e   r re es se ea ar rc ch h
Several centres have already adopted a shortened
protocol for counselees who apply for BRCA1/2 genetic
susceptibility testing and in the United Kingdom certain
centres have shortened the protocol for HNPCC pre-test
counselling [26]. Aktan-Collan et al [27] evaluated
a shortened protocol for predictive testing for HNPCC,
that consisted of two sessions and no provision of
additional psychological support. The majority (88%)
of counselees were satisfied with the procedure and
suggested no changes. The counselees who suggested
changes generally asked for more written material, not
for more counselling sessions. However half of the
counselees  indicated  that  they  might  have  used
psychological support if it had been offered to them. 
Given these results, we think it is unlikely that the
proposed counselling protocol for BRCA1/2 genetic
susceptibility testing results in an increase in adverse
psychological reactions, but more research is necessary
to  evaluate  which  aspects  of  genetic  counselling
contribute to thorough decision making [28] and to the
emotional well-being of counselees and their partners.
Future research should also aim at determining the
characteristics of individuals who might benefit from
additional psychological support and at disentangling
the psychological processes resulting in ineffective coping.
This knowledge will enable us to identify these individuals
as precisely as possible and to adjust our counselling
further to the individual needs of the counselees. 
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